ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab

As the biggest and brightest in the blood cancer world came together for the ASH conference this weekend, European biotech Argenx was busy making a big biobucks deal.

It has teamed up with Cilag, a subsidiary of Janssen, to work on the company’s cusatuzumab.